The SGLT2 inhibitor empagliflozin inhibits skeletal muscle fibrosis in naturally aging male mice through the AMPKα/MMP9/TGF-β1/Smad pathway
Biogerontology · 2024
DOI: 10.1007/s10522-024-10093-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Biogerontology, 2024. Verfasst von Qixuan Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China. Hauptthemen laut MEDLINE: Aging, AMP-Activated Protein Kinases, Benzhydryl Compounds, Fibrosis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Chongqing Municipal Health Commission, Chongqing Municipal Bureau of Science and Technology.
Abstract (Originalsprache)
ABSTACT: With advancing age, the incidence of sarcopenia increases, eventually leading to a cascade of adverse events. However, there is currently a lack of effective pharmacological treatment for sarcopenia. Sodium-glucose co-transporter 2 inhibitor (SGLT2i) empagliflozin demonstrates anti-fibrotic capabilities in various organs. This study aims to determine whether empagliflozin can improve skeletal muscle fibrosis induced by sarcopenia in naturally aging mice. A natural aging model was established by feeding male mice from 13 months of age to 19 months of age. A fibrosis model was created by stimulating skeletal muscle fibroblasts with TGF-β1. The Forelimb grip strength test assessed skeletal muscle function, and expression levels of COL1A1, COL3A1, and α-SMA were analyzed by western blot, qPCR, and immunohistochemistry. Additionally, levels of AMPKα/MMP9/TGFβ1/Smad signaling pathways were examined. In naturally aging mice, skeletal muscle function declines, expression of muscle fibrosis markers increases, AMPKα expression is downregulated, and MMP9/TGFβ1/Smad signaling pathways are upregulated. However, treatment with empagliflozin reverses this phenomenon. At the cellular level, empagliflozin exhibits similar anti-fibrotic effects, and these effects are attenuated by Compound C and siAMPKα. Empagliflozin exhibits anti-fibrotic effects, possibly associated with the AMPK/MMP9/TGFβ1/Smad signaling pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
- Department of Endocrinology, The Ninth People's Hospital of Chongqing, Chongqing, 400700, China.
- Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
- Department of Endocrinology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China. ldf023023@qq.com.
Förderung
- Chongqing Municipal Health Commission
- Chongqing Municipal Bureau of Science and Technology
Zitieren
APA
Huang, Q., Chen, J., Liao, S., Long, J., Fang, R., He, Y., Chen, P., & Liu, D. (2024). The SGLT2 inhibitor empagliflozin inhibits skeletal muscle fibrosis in naturally aging male mice through the AMPKα/MMP9/TGF-β1/Smad pathway. Biogerontology. https://doi.org/10.1007/s10522-024-10093-y
Vancouver
Huang Q, Chen J, Liao S, Long J, Fang R, He Y, et al. The SGLT2 inhibitor empagliflozin inhibits skeletal muscle fibrosis in naturally aging male mice through the AMPKα/MMP9/TGF-β1/Smad pathway. Biogerontology. 2024. doi:10.1007/s10522-024-10093-y
BibTeX
@article{Huang2024,
author = {Huang, Qixuan and Chen, Jie and Liao, Siqi and Long, Jiangchuan and Fang, Ronghua and He, Yusen and Chen, Peiyun and Liu, Dongfang},
title = {The SGLT2 inhibitor empagliflozin inhibits skeletal muscle fibrosis in naturally aging male mice through the AMPKα/MMP9/TGF-β1/Smad pathway},
journal = {Biogerontology},
year = {2024},
doi = {10.1007/s10522-024-10093-y}
}
EUVIMED